Meloxicam SBEβCD Composition for Poor Solubility and Fast Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to complex with meloxicam. The cyclodextrin-meloxicam inclusion complex serves as a mediator that improves aqueous solubility and bioavailability without altering the inherent properties of meloxicam itself. This resolves the contradiction by introducing a third substance that facilitates drug delivery.
Solution Approach 2:
The patent changes the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This complexation alters the solubility parameters and absorption characteristics of meloxicam, transforming it from a poorly soluble drug to a bioavailable formulation while maintaining its therapeutic efficacy.
2Speed
If meloxicam is administered conventionally, then it provides pain relief, but the onset of pain relief is slow due to poor solubility
Solution Approach 1:
Cyclodextrins act as intermediary carriers that facilitate rapid dissolution and absorption of meloxicam. The inclusion complex structure allows meloxicam to be delivered quickly to the absorption site, significantly accelerating the onset of pain relief compared to conventional administration.
Solution Approach 2:
The cyclodextrin-meloxicam complex is prepared in advance in a soluble form, allowing the drug to be ready for rapid absorption upon administration. This preliminary complexation action ensures that no time is lost during the absorption phase, enabling faster onset of therapeutic effect.
3Reliability
If cyclodextrins are used to increase solubility of meloxicam, then bioavailability is enhanced, but the formulation complexity increases
Solution Approach 1:
The patent combines meloxicam with cyclodextrins in a single inclusion complex formulation, merging the drug delivery function and solubility enhancement function into one integrated system. This unified approach improves bioavailability while avoiding the need for multiple separate formulation components or complex delivery systems.
Solution Approach 2:
The cyclodextrin-meloxicam inclusion complex is designed to automatically dissolve and release meloxicam in the body without requiring additional excipients, special delivery mechanisms, or complex formulation steps. The self-dissolving nature of the complex simplifies the overall formulation while maintaining enhanced bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.